76801-94-0

Basic information

• Product Name: 5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate
• Synonyms: 5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate;5-Amino-N,Na€-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide Tetraacetate
• CAS NO: 76801-94-0
• Molecular Formula: C₂₂H₂₆I₃N₃O₁₀
• Molecular Weight: 873.16935
• Product Categories: Aromatics, Isotope Labelled Compounds, Labeling and Diagnostics Reagents
• Mol File: 76801-94-0.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Solubility: Chloroform, Dichloromethane
• CAS DataBase Reference: 5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate(76801-94-0)
• EPA Substance Registry System: 5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate(76801-94-0)

Safety Data

• Hazardous Substances Data: 76801-94-0(Hazardous Substances Data)

Usage

Chemical Properties

Beige Solid

Uses

5-Amino-N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide Tetraacetate is an intermediate in the preparation of X-ray contrast agents such as Iohexol (I729500), Ioversol (I737000), Ioxilan (I737500), Iopamidol (I735600).

Upstream product

• 111453-32-8 5-amino-N-(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamic acid 
• 37441-29-5 5-amino-2,4,6-triiodoisophthalic acid dichloride 
• 35453-19-1 2,4,6-triiodo-5-aminoisophthalic acid 
• 99-31-0 5-aminoisophthalic acid 
• 76801-93-9 5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide 
• 108-24-7 acetic anhydride 

Downstream Products

• 136452-99-8 acetic acid 2-acetoxy-3-[3-(2,3-diacetoxy-propylcarbamoyl)-2,4,6-triiodo-5-isocyanato-benzoylamino]-propyl-1-ester 
• 136453-21-9 N,N'-Bis<2,3-bis(acetyloxy)propyl>-2,4,6-triiodo-5-<<(2-propenyloxy)acetyl>amino>-1,3-benzenedicarboxamide 
• 136453-13-9 N,N'-bis[2,3-bis(acetyloxy)propyl]-5-[(2,5-dibromo-1-oxopentyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 182758-15-2 N,N'-Bis[2,3-bis(acetyloxy)-1-propyl]-5-[(2,6-dibromo-1-oxo-hexyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 136453-08-2 N,N'-Bis-[2,3-diacetyloxypropyl]-5-[3-bromo-2-oxo-1-pyrrolidinyl]-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 136453-19-5 N,N'-bis-[2,3-bis-(acetyloxy)-1-propyl]-5-[4-chloro-1-oxobutyl]-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 136453-24-2 N,N'-Bis[2,3-bis(Acetyloxy)propyl]-5-[(5-chloro-1-oxo-pentyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 78649-41-9 iomeprol 
• 87785-51-1 5-(acetoxyacetylamino)-N,N'-bis(2,3-diacetoxypropyl)-2,4,6-triiodoisophthalamide 
• 166818-25-3 N,N'-Bis<2,3-bis(acetyloxy)propyl>-5-<3-<(acetyloxy)methyl>-5-oxo-4-morpholinyl>-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 166818-22-0 5-<2-<(Acetyloxy)methyl>-5-oxo-1-pyrrolidinyl>-N,N'-bis(acetyloxy)propyl-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 136453-22-0 N,N'-Bis<2,3-bis(acetyloxy)propyl>-2,4,6-triiodo-5-<3-(iodomethyl)-5-oxo-4-morpholinyl>-1,3-benzenedicarboxamide 
• 148051-07-4 5-<<5-<(Acetyloxy)methyl>dihydro-2(3H)-furanylidene>amino>-N,N'-bis(acetyloxy)propyl-2,4,6-triiodo-1,3-benzenedicarboxamide 
• 136452-88-5 N,N'-Bis<2,3-bis(acetyloxy)propyl>-5-<2-(iodomethyl)-5-oxo-1-pyrrolidinyl>-2,4,6-triiodo-1,3-benzenedicarboxamide 

Relevant articles and documents

NOVEL INTERMEDIATE COMPOUND AND PREPARATION PROCESS OF IOMEPROL USING THEREOF

The present invention relates to a novel intermediate compound of iomeprol, a production method thereof, and a method for producing iomeprol using the same. More specifically, the present invention relates to a method for producing iomeprol used as X-ray vascular contrast agents in an economically feasible way with high purity using a novel intermediate N,Nandprime;-bis(2,3-diacetylatepropyl)-5-(2-acetoxy-N-methylacetoamide)-2,4,6-triiodoisophthalamide. The present invention further relates to a purification method thereof.COPYRIGHT KIPO 2017

CONTRAST AGENTS AND DIAGNOSTIC COMPOSITIONS BASED ON IODINE-CONTAINING CYANURIC ACID DERIVATIVES

The present invention relates to a class of compounds of Formula (I) and to diagno stic compositions containing such compounds where the compounds are iodine conta ining compounds. More specifically the iodine containing compounds are chemical compounds containing a cyanuric acid scaffolding moiety allowing for the arrange ment of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imag ing and in particular in X-ray imaging and to contrast media containing such com pounds .

Starch microspheres as carriers for X-ray imaging contrast agents: Synthesis and stability of new amino-acid linker derivatives

The relative stability of particulate contrast agents for X-ray imaging, consisting of a succinic-acid derivative of a water-soluble X-ray contrast agent bound to starch particles through an amino-acid ester bond, has been studied. To investigate the effect of chain length of the amino-acid linker on degradation rate, two glycine-linked derivatives and a corresponding β-alanine-linked derivative were prepared as model compounds. The cleavage rate of the amino-acid ester bond in the starch particle β-alanine derivative had a significantly lower cleavage rate than in the corresponding glycine derivatives; after 22 h in human blood serum at 37°C the remaining fraction of the undegraded β-alanine-linked derivative was 78%, while 31.1 and 29.3% were the remaining fractions of the two glycine-linked derivatives. The cleavage data correlated well with biphasic cleavage processes with two distinct half lives for the respective pseudo first order processes. The second preparation with the glycine linker had a cleavage profile and rate equivalent to that of the first one in human blood serum, but the corresponding hydrolysis in phosphate buffer was significantly slower with 79.9%-remaining fraction after 22 h, and was apparently a monophasic pseudo first order reaction. Variation of the degradability of the starch matrix had apparently no significant effect on the cleavage rates of the linker. This suggests that components in the human blood serum catalyze the cleavage of the ester bond in these derivatives and that a fraction of the covalently bound contrast agent had a significantly slower cleavage rate from the matrix. The derivative with a glycine linker between the carrier matrix and the contrast agent is a promising candidate for liver and spleen directed X-ray contrast with respect to density of contrast generating iodine and biodegradability.